<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566111</url>
  </required_header>
  <id_info>
    <org_study_id>06T-812</org_study_id>
    <secondary_id>HIC#0704002567</secondary_id>
    <nct_id>NCT00566111</nct_id>
  </id_info>
  <brief_title>Ceftriaxone in the Management of Bipolar Depression</brief_title>
  <official_title>Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient,
      placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar
      disorder, currently depressed, who have failed to respond to conventional treatments.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early indication of an unfavorable risk/benefit ratio.
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of patients with scores that decreased at four weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Score on the 16-item Quick Inventory of Depressive Symptoms (QIDS) From Baseline.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of patients with scores that decreased at four weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Achieve Remission as Defined by a HDRS Score &lt; 7.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery Asberg Depression Rating Scale (MADRS)Score From Baseline.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number of patients that had a decrease on MADRS at 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number of patients that had a decrease on CGI-BP at 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Rocephin</other_name>
    <other_name>Ceftriaxone Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of bipolar disorder

          -  Presence of a current major depressive episode on the SCID

          -  Score of 17 or greater on the HDRS

          -  Failure to respond to two previous medication trials

          -  Capable of giving voluntary written consent

        Exclusion Criteria:

          -  Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis

          -  Significant current substance dependence/abuse within 3 months preceding the trial

          -  Significant history of intravenous drug abuse

          -  Active suicidal ideation

          -  Pregnant/lactating mothers

          -  Significant medical history

          -  Patients on anticoagulation treatment

          -  Patients who test positive for HIV or Hep B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zubin Bhagwagar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Sanacora, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry. 2007 Jan 15;61(2):250-2. Epub 2006 Jul 24.</citation>
    <PMID>16860779</PMID>
  </reference>
  <reference>
    <citation>Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005 Jan 6;433(7021):73-7.</citation>
    <PMID>15635412</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <results_first_submitted>August 25, 2016</results_first_submitted>
  <results_first_submitted_qc>August 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2016</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ceftriaxone</keyword>
  <keyword>Acute Antidepressant Effects</keyword>
  <keyword>Glutamatergic System</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Mood Disorders</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Affective Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ceftriaxone</title>
          <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceftriaxone</title>
          <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline.</title>
        <description>Number of patients with scores that decreased at four weeks.</description>
        <time_frame>4 weeks</time_frame>
        <population>only participants with complete data at 4 weeks were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline.</title>
          <description>Number of patients with scores that decreased at four weeks.</description>
          <population>only participants with complete data at 4 weeks were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on the 16-item Quick Inventory of Depressive Symptoms (QIDS) From Baseline.</title>
        <description>Number of patients with scores that decreased at four weeks.</description>
        <time_frame>4 weeks</time_frame>
        <population>These data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on the 16-item Quick Inventory of Depressive Symptoms (QIDS) From Baseline.</title>
          <description>Number of patients with scores that decreased at four weeks.</description>
          <population>These data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Achieve Remission as Defined by a HDRS Score &lt; 7.</title>
        <time_frame>4 weeks</time_frame>
        <population>only participants with complete data at 4 weeks were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieve Remission as Defined by a HDRS Score &lt; 7.</title>
          <population>only participants with complete data at 4 weeks were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Montgomery Asberg Depression Rating Scale (MADRS)Score From Baseline.</title>
        <description>The number of patients that had a decrease on MADRS at 4 weeks.</description>
        <time_frame>4 weeks</time_frame>
        <population>only participants with complete data at 4 weeks were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montgomery Asberg Depression Rating Scale (MADRS)Score From Baseline.</title>
          <description>The number of patients that had a decrease on MADRS at 4 weeks.</description>
          <population>only participants with complete data at 4 weeks were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).</title>
        <description>The number of patients that had a decrease on CGI-BP at 4 weeks.</description>
        <time_frame>4 weeks</time_frame>
        <population>only patients with complete data at 4 weeks were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).</title>
          <description>The number of patients that had a decrease on CGI-BP at 4 weeks.</description>
          <population>only patients with complete data at 4 weeks were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ceftriaxone</title>
          <description>ceftriaxone: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline solution: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Difficulty Concentrating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Poor Coordination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gerard Sanacora</name_or_title>
      <organization>Yale University Department of Psychiatry</organization>
      <phone>(203) 974-7535</phone>
      <email>gerard.sanacora@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

